INMB INmune Bio, Inc.
USHealthcareAs of 2026-07-15
Why INMB matters now
INmune Bio, Inc. (INMB) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.07 with +2.48% on the session and $55.0M in market capitalization; recent performance reads 1-month +2.84% and YTD -7.05%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.4M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -53.9%.
The latest indexable market news headline is "INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.96
P/S
0.00
EV/EBITDA
-0.75
DCF Value
$0.76
FCF Yield
-53.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-170.9%
ROA
-161.1%
ROIC
-204.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.4M | $-0.20 |
| Q4 2025 | $0.00 | $-5.3M | $-0.20 |
| FY 2025 | $50.0K | $-45.9M | $-1.86 |
| Q3 2025 | $0.00 | $-6.5M | $-0.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$22.00
Target (Median)
$22.00
Target Range
$22.00 - $22.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.01
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.